Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment

Overview

Journal Nanomaterials (Basel)

Date 2023 May 27

PMID 37242072

Authors

Shahinur Acter

Michele Moreau

Robert Ivkov

Akila Viswanathan

Wilfred Ngwa

Affiliations

Soon will be listed here.

Abstract

In efforts to overcome current challenges in cancer treatment, multifunctional nanoparticles are attracting growing interest, including nanoparticles made with polydopamine (PDA). PDA is a nature-inspired polymer with a dark brown color. It has excellent biocompatibility and is biodegradable, offering a range of extraordinary inherent advantages. These include excellent drug loading capability, photothermal conversion efficiency, and adhesive properties. Though the mechanism of dopamine polymerization remains unclear, PDA has demonstrated exceptional flexibility in engineering desired morphology and size, easy and straightforward functionalization, etc. Moreover, it offers enormous potential for designing multifunctional nanomaterials for innovative approaches in cancer treatment. The aim of this work is to review studies on PDA, where the potential to develop multifunctional nanomaterials with applications in photothermal therapy has been demonstrated. Future prospects of PDA for developing applications in enhancing radiotherapy and/or immunotherapy, including for image-guided drug delivery to boost therapeutic efficacy and minimal side effects, are presented.

Citing Articles

Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.

Appidi T, China D, Stefan G, Moreau M, Mao S, Velarde E Mol Cancer. 2025; 24(1):68.

PMID: 40050802 PMC: 11883980. DOI: 10.1186/s12943-025-02266-1.

Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.

Zhu K, Wang K, Zhang R, Zhu Z, Wang W, Yang B J Nanobiotechnology. 2025; 23(1):112.

PMID: 39955554 PMC: 11829476. DOI: 10.1186/s12951-025-03197-1.

PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System.

Acter S, Ngema L, Moreau M, China D, Viswanathan A, Ding K Pharmaceutics. 2024; 16(11).

PMID: 39598603 PMC: 11597857. DOI: 10.3390/pharmaceutics16111481.

Toxicity and Oxidative Stress Biomarkers in the Organs of Mice Treated with Mesoporous Polydopamine Nanoparticles Modified with Iron and Coated with Cancer Cell Membrane.

Szukalska M, Grzeskowiak B, Bigaj-Jozefowska M, Witkowska M, Cicha E, Sujka-Kordowska P Int J Nanomedicine. 2024; 19:12053-12078.

PMID: 39583321 PMC: 11585271. DOI: 10.2147/IJN.S481120.

Polydopamine Nanobowl-Armoured Perfluorocarbon Emulsions: Tracking Thermal- and Photothermal-Induced Phase Change through Neutron Scattering.

Vidallon M, Liu H, Lu Z, Acter S, Song Y, Baldwin C Small. 2024; 21(2):e2406019.

PMID: 39523733 PMC: 11735900. DOI: 10.1002/smll.202406019.

References

Mundekkad D, Cho W . Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci. 2022; 23(3). PMC: 8835852. DOI: 10.3390/ijms23031685. View

Lu Z, Acter S, Teo B, Tabor R . Synthesis and characterisation of polynorepinephrine-shelled microcapsules an oil-in-water emulsion templating route. J Mater Chem B. 2021; 9(46):9575-9582. DOI: 10.1039/d1tb01786a. View

Sajja H, East M, Mao H, Wang Y, Nie S, Yang L . Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol. 2009; 6(1):43-51. PMC: 3108242. DOI: 10.2174/157016309787581066. View

Jindal A . The effect of particle shape on cellular interaction and drug delivery applications of micro- and nanoparticles. Int J Pharm. 2017; 532(1):450-465. DOI: 10.1016/j.ijpharm.2017.09.028. View

Ridolfo R, Tavakoli S, Junnuthula V, Williams D, Urtti A, van Hest J . Exploring the Impact of Morphology on the Properties of Biodegradable Nanoparticles and Their Diffusion in Complex Biological Medium. Biomacromolecules. 2020; 22(1):126-133. PMC: 7805011. DOI: 10.1021/acs.biomac.0c00726. View

Wang X, Zhang H, Chen X . Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2021; 2:141-160. PMC: 8315569. DOI: 10.20517/cdr.2019.10. View

Hao Y, Altundal Y, Moreau M, Sajo E, Kumar R, Ngwa W . Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation. Phys Med Biol. 2015; 60(18):7035-43. PMC: 4946866. DOI: 10.1088/0031-9155/60/18/7035. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Mueller R, Moreau M, Yasmin-Karim S, Protti A, Tillement O, Berbeco R . Imaging and Characterization of Sustained Gadolinium Nanoparticle Release from Next Generation Radiotherapy Biomaterial. Nanomaterials (Basel). 2020; 10(11). PMC: 7697013. DOI: 10.3390/nano10112249. View

10.

Yuen C, Liu Q . Magnetic field enriched surface enhanced resonance Raman spectroscopy for early malaria diagnosis. J Biomed Opt. 2012; 17(1):017005. DOI: 10.1117/1.JBO.17.1.017005. View

11.

Siciliano G, Monteduro A, Turco A, Primiceri E, Rizzato S, Depalo N . Polydopamine-Coated Magnetic Iron Oxide Nanoparticles: From Design to Applications. Nanomaterials (Basel). 2022; 12(7). PMC: 9000600. DOI: 10.3390/nano12071145. View

12.

Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A . Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation time . Asian J Pharm Sci. 2021; 16(4):444-458. PMC: 8520042. DOI: 10.1016/j.ajps.2020.07.005. View

13.

Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M . Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2013; 3(3):3279-330. PMC: 3759197. DOI: 10.3390/cancers3033279. View

14.

Murugan K, Choonara Y, Kumar P, Bijukumar D, du Toit L, Pillay V . Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine. 2015; 10:2191-206. PMC: 4370919. DOI: 10.2147/IJN.S75615. View

15.

van der Meel R, Lammers T, Hennink W . Cancer nanomedicines: oversold or underappreciated?. Expert Opin Drug Deliv. 2016; 14(1):1-5. PMC: 5404718. DOI: 10.1080/17425247.2017.1262346. View

16.

Ma P, Mumper R . Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol. 2013; 4(2):1000164. PMC: 3806207. DOI: 10.4172/2157-7439.1000164. View

17.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

18.

Zhou X, Chang T, Chen S, Liu T, Wang H, Liang J . Polydopamine-Decorated Orlistat-Loaded Hollow Capsules with an Enhanced Cytotoxicity against Cancer Cell Lines. Mol Pharm. 2019; 16(6):2511-2521. DOI: 10.1021/acs.molpharmaceut.9b00116. View

19.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

20.

Cheng W, Zeng X, Chen H, Li Z, Zeng W, Mei L . Versatile Polydopamine Platforms: Synthesis and Promising Applications for Surface Modification and Advanced Nanomedicine. ACS Nano. 2019; 13(8):8537-8565. DOI: 10.1021/acsnano.9b04436. View